We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
Read MoreHide Full Article
Wall Street has remained volatile in 2025 due to the highly overstretched valuation of U.S. stocks, sticky inflation, several weak economic data, geopolitical conflicts and severe concerns related to the Trump administration’s tariff and trade policies.
Moreover, the Fed’s ambiguity over further rate cuts in 2025, concerns of a near-term recession and the availability of a low-cost Chinese AI platform have unnerved investors resulting in volatile trading.
At this stage, it should be prudent to invest in stocks of high dividend-paying corporate bigwigs. These firms generally have a strong financial position, robust business model and globally acclaimed brand value. Further, their regular dividend payment will act as income stream during market fluctuations.
The chart below shows the price performance of our five picks in the past three months.
Image Source: Zacks Investment Research
Philip Morris International Inc.
Zacks Rank #1 Philip Morris has benefited from strong pricing power and an expanding smoke-free product portfolio. PM has been making significant progress on its smoke-free transition, with products like IQOS and ZYN contributing to strong performance. In fact, PM aims to become substantially smoke-free by 2030.
Philip Morris is set for another year of robust growth in 2025, driven by increasing demand across all product categories. PM anticipates positive volume growth for the fifth consecutive year, with an expected increase of 2%. Smoke-free products remain a key growth driver, projected to expand by 12-14%, reinforcing PM’s strategic shift toward reduced-risk alternatives.
Philip Morris has an expected revenue and earnings growth rate of 8.1% and 13.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 4.6% over the last 60 days. PM has a current dividend-yield of 3.01%.
CVS Health Corp.
Zacks Rank #2 CVS Health is investing in advanced technological capabilities to cut down costs and improve customer experience. Improved Medicare Advantage star ratings for the 2025 payment year are a positive development for CVS.
To stay competitive, CVS regularly reviews its national footprint, planning to close 271 stores and save more than $500 million in 2025. Oak Street Health continues to demonstrate strong patient growth, boosting the Healthcare delivery business. In Pharmacy and Consumer Wellness, CVS maintains a strong retail pharmacy script share position despite the reduced store count.
CVS Health has an expected revenue and earnings growth rate of 3.7% and 12.6%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.6% over the last 30 days. CVS has a current dividend-yield of 4.34%.
Energy Transfer LP
Zacks Rank #2 Energy Transfer is poised to benefit from long-term fee-based commitments. Nearly 90% of its earnings are from fee-based contracts and 10% from commodity and spread exposure. ET is also focused on expanding operations through organic and inorganic initiatives.
ET is looking for solutions to meet growing energy demands from additional demand centers through its pipeline network. ET’s systematic investments should boost its total fractionation capacity at Mont Belvieu and raise its top line.
ET is expected to maintain its well-balanced growth strategy, which includes internal expansion, strategic acquisitions, actions to boost the profitability of its existing assets, and, where necessary, the use of cost-control measures to manage its operations.
By taking additional measures to improve utilization, lowering costs through improved operations, and adding new volumes under long-term producer agreements, ET seeks to improve the profitability of the existing asset base.
Energy Transfer has an expected revenue and earnings growth rate of 18.2% and 12.5%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.9% over the last 30 days. ET has a current dividend-yield of 7.30%.
GSK plc
Zacks Rank #2 GSK enjoys a strong position in HIV and Vaccines therapeutic areas. GSK is witnessing increased sales growth of the Specialty Medicines unit, particularly reflecting successful new launches in Oncology and of long-acting HIV medicines. GSK has some promising new products in Specialty Medicines like cancer drugs, Ojjaara and Jemperli. Sales are also improving in its General Medicines unit.
GSK’s key products like Nucala (four IL-5 medicated conditions), Trelegy Ellipta (three medicines in a single inhaler to treat COPD), Juluca (dolutegravir+ rilpivirine once-daily, single pill for HIV) and Dovato (dolutegravir + lamivudine in a single tablet for HIV) have witnessed considerable success and have become key drivers of top-line growth.
GSK has increased R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. The company has 70 assets in clinical development.
GSK has an expected revenue and earnings growth rate of 5.1% and 6.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.7% over the last seven days. GSK has a current dividend-yield of 4.28%.
NatWest Group plc
Zacks Rank #1 NatWest Group provides banking and financial products and services to personal, commercial, corporate, and institutional customers in the United Kingdom and internationally. NWG operates through Retail Banking, Private Banking, and Commercial & Institutional segments.
NWG provides personal and business banking, consumer loans, asset and invoice finances, commercial and residential mortgages, credit cards and financial planning services, as well as life, personal and income protection insurance.
NatWest Group has an expected revenue and earnings growth rate of 20.1% and 17.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 6.8% over the last 30 days. NWG has a current dividend-yield of 5.41%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
Wall Street has remained volatile in 2025 due to the highly overstretched valuation of U.S. stocks, sticky inflation, several weak economic data, geopolitical conflicts and severe concerns related to the Trump administration’s tariff and trade policies.
Moreover, the Fed’s ambiguity over further rate cuts in 2025, concerns of a near-term recession and the availability of a low-cost Chinese AI platform have unnerved investors resulting in volatile trading.
At this stage, it should be prudent to invest in stocks of high dividend-paying corporate bigwigs. These firms generally have a strong financial position, robust business model and globally acclaimed brand value. Further, their regular dividend payment will act as income stream during market fluctuations.
Five such corporate behemoths with a favorable Zacks Rank are: Philip Morris International Inc. (PM - Free Report) , CVS Health Corp. (CVS - Free Report) , Energy Transfer LP (ET - Free Report) , GSK plc (GSK - Free Report) and NatWest Group plc (NWG - Free Report) . Each of our picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The chart below shows the price performance of our five picks in the past three months.
Image Source: Zacks Investment Research
Philip Morris International Inc.
Zacks Rank #1 Philip Morris has benefited from strong pricing power and an expanding smoke-free product portfolio. PM has been making significant progress on its smoke-free transition, with products like IQOS and ZYN contributing to strong performance. In fact, PM aims to become substantially smoke-free by 2030.
Philip Morris is set for another year of robust growth in 2025, driven by increasing demand across all product categories. PM anticipates positive volume growth for the fifth consecutive year, with an expected increase of 2%. Smoke-free products remain a key growth driver, projected to expand by 12-14%, reinforcing PM’s strategic shift toward reduced-risk alternatives.
Philip Morris has an expected revenue and earnings growth rate of 8.1% and 13.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 4.6% over the last 60 days. PM has a current dividend-yield of 3.01%.
CVS Health Corp.
Zacks Rank #2 CVS Health is investing in advanced technological capabilities to cut down costs and improve customer experience. Improved Medicare Advantage star ratings for the 2025 payment year are a positive development for CVS.
To stay competitive, CVS regularly reviews its national footprint, planning to close 271 stores and save more than $500 million in 2025. Oak Street Health continues to demonstrate strong patient growth, boosting the Healthcare delivery business. In Pharmacy and Consumer Wellness, CVS maintains a strong retail pharmacy script share position despite the reduced store count.
CVS Health has an expected revenue and earnings growth rate of 3.7% and 12.6%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.6% over the last 30 days. CVS has a current dividend-yield of 4.34%.
Energy Transfer LP
Zacks Rank #2 Energy Transfer is poised to benefit from long-term fee-based commitments. Nearly 90% of its earnings are from fee-based contracts and 10% from commodity and spread exposure. ET is also focused on expanding operations through organic and inorganic initiatives.
ET is looking for solutions to meet growing energy demands from additional demand centers through its pipeline network. ET’s systematic investments should boost its total fractionation capacity at Mont Belvieu and raise its top line.
ET is expected to maintain its well-balanced growth strategy, which includes internal expansion, strategic acquisitions, actions to boost the profitability of its existing assets, and, where necessary, the use of cost-control measures to manage its operations.
By taking additional measures to improve utilization, lowering costs through improved operations, and adding new volumes under long-term producer agreements, ET seeks to improve the profitability of the existing asset base.
Energy Transfer has an expected revenue and earnings growth rate of 18.2% and 12.5%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.9% over the last 30 days. ET has a current dividend-yield of 7.30%.
GSK plc
Zacks Rank #2 GSK enjoys a strong position in HIV and Vaccines therapeutic areas. GSK is witnessing increased sales growth of the Specialty Medicines unit, particularly reflecting successful new launches in Oncology and of long-acting HIV medicines. GSK has some promising new products in Specialty Medicines like cancer drugs, Ojjaara and Jemperli. Sales are also improving in its General Medicines unit.
GSK’s key products like Nucala (four IL-5 medicated conditions), Trelegy Ellipta (three medicines in a single inhaler to treat COPD), Juluca (dolutegravir+ rilpivirine once-daily, single pill for HIV) and Dovato (dolutegravir + lamivudine in a single tablet for HIV) have witnessed considerable success and have become key drivers of top-line growth.
GSK has increased R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. The company has 70 assets in clinical development.
GSK has an expected revenue and earnings growth rate of 5.1% and 6.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.7% over the last seven days. GSK has a current dividend-yield of 4.28%.
NatWest Group plc
Zacks Rank #1 NatWest Group provides banking and financial products and services to personal, commercial, corporate, and institutional customers in the United Kingdom and internationally. NWG operates through Retail Banking, Private Banking, and Commercial & Institutional segments.
NWG provides personal and business banking, consumer loans, asset and invoice finances, commercial and residential mortgages, credit cards and financial planning services, as well as life, personal and income protection insurance.
NatWest Group has an expected revenue and earnings growth rate of 20.1% and 17.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 6.8% over the last 30 days. NWG has a current dividend-yield of 5.41%.